9.7.2013   

EN

Official Journal of the European Union

C 196/1

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32013M6883. EUR-Lex is the on-line access to the European law.

9.7.2013   

EN

Official Journal of the European Union

C 196/1

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32013M6897. EUR-Lex is the on-line access to the European law.

9.7.2013   

EN

Official Journal of the European Union

C 196/2

9.7.2013   

EN

Official Journal of the European Union

C 196/3

1.

On 1 July 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Valeant Pharmaceuticals International, Inc. (‘Valeant’), a publicly held company established under the laws of Canada, acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Bausch & Lomb Holdings Incorporated (‘Bausch & Lomb’), a privately held company headquartered in Rochester, NY, USA, by way of purchase of shares.

2.

The business activities of the undertakings concerned are:

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6969 — Valeant Pharmaceuticals International/Bausch & Lomb Holdings, to the following address:

9.7.2013   

EN

Official Journal of the European Union

C 196/4

1.

On 28 June 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Archer-Daniels-Midland (‘ADM’, US) acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the undertaking GrainCorp Limited (‘GrainCorp’, Australia), by way of purchase of shares.

2.

The business activities of the undertakings concerned are:

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6963 — Archer-Daniels-Midland Company/GrainCorp, to the following address:

9.7.2013   

EN

Official Journal of the European Union

C 196/5

1.

On 1 July 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking NBIM Clement SCI, an indirectly wholly owned subsidiary of Norges Bank (Norway) acquires within the meaning of Article 3(1)(b) of the Merger Regulation joint control over SCI Pasquier, SCI Malesherbes, SCI Daumesnil, SCI 15 Scribe and SAS 100 CE, (together ‘The Target’, France) together with Assicurazioni Generali (Italy) by the way of acquisition of shares.

2.

The business activities of the undertakings concerned are:

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6934 — Norges Bank/Generali/Group of buildings in Paris, to the following address: